Aureus Pharma to join Biointelligence programme
Promoting the use of systemic modelling and simulation tools to improve research efficiency
Aureus Pharma, a French provider of knowledge management systems to accelerate discovery in the life sciences, is to participate in the €118.2m (US$160m) Biointelligence r&d programme, which aims to promote the use of systemic modelling and simulation tools to exploit biomedical databases and optimise the research phases of drug development.
Dassault Systèmes is co-ordinating the scheme, which will involve Sanofi-Aventis, Ipsen, Servier, Pierre Fabre, Bayer Cropscience, as well as public research institutes Inserm, Inria and Genopole, and bioinformatics’ SMEs Aureus and Sobios.
Aureus will participate in the development of the Knowledge Management layer of the system and build content in therapeutic areas such as oncology, as well as in the areas of nuclear receptors, proteases inhibitors and life science semantics.
The programme will also enable Aureus to evolve its data models to integrate more complex drug and drug candidate properties, biological protocols or regulation of physiological responses. Aureus Pharma expects to receive a total of €3.5m in funding, but further details are not being made public.
‘Aureus brings its long-term experience in organising and structuring scientific data into knowledge. This programme will provide Aureus with further resources and insight on scientists' specific needs and sustain the development of new innovative products to continue serving our market,’ said Dr Jason Theodosiou, president and chief executive of Aureus Pharma.
